{"id":"NCT00518089","sponsor":"Allergan","briefTitle":"A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2009-01","completion":"2009-01","firstPosted":"2007-08-20","resultsPosted":"2011-11-30","lastUpdate":"2019-04-23"},"enrollment":859,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Gatifloxacin 0.5% eye drops","otherNames":[]},{"type":"DRUG","name":"placebo eye drops","otherNames":[]}],"arms":[{"label":"Gatifloxacin 0.5% Eye Drops","type":"EXPERIMENTAL"},{"label":"Placebo Eye Drops","type":"PLACEBO_COMPARATOR"}],"summary":"The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis","primaryOutcome":{"measure":"Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6","timeFrame":"6 Days","effectByArm":[{"arm":"Gatifloxacin 0.5% Eye Drops","deltaMin":51.8,"sd":null},{"arm":"Placebo Eye Drops","deltaMin":41.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":2,"countries":["United States","India"]},"refs":{"pmids":["25244402"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":429},"commonTop":["Conjunctivitis bacterial","Eye Irritation"]}}